

Adam L Halberstadt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/46282/publications.pdf>

Version: 2024-02-01

69
papers

3,965
citations

117453

34
h-index

128067

60
g-index

70
all docs

70
docs citations

70
times ranked

2986
citing authors

#	ARTICLE	IF	CITATIONS
1	Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Archives of General Psychiatry, 2011, 68, 71.	13.8	806
2	Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 2011, 61, 364-381.	2.0	274
3	Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research, 2015, 277, 99-120.	1.2	221
4	Characterization of the head-twitch response induced by hallucinogens in mice. Psychopharmacology, 2013, 227, 727-739.	1.5	139
5	Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. Journal of Psychopharmacology, 2011, 25, 1548-1561.	2.0	135
6	Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology, 2020, 167, 107933.	2.0	132
7	5-HT _{2A} and 5-HT _{2C} Receptors Exert Opposing Effects on Locomotor Activity in Mice. Neuropsychopharmacology, 2009, 34, 1958-1967.	2.8	127
8	International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacological Reviews, 2021, 73, 310-520.	7.1	127
9	PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program. Journal of Psychoactive Drugs, 2014, 46, 73-77.	1.0	103
10	The Phencyclidine-Glutamate Model of Schizophrenia. Clinical Neuropharmacology, 1995, 18, 237-249.	0.2	95
11	Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology, 2014, 77, 200-207.	2.0	95
12	Four factors underlying mouse behavior in an open field. Behavioural Brain Research, 2012, 233, 55-61.	1.2	77
13	Pharmacology and Toxicology of N-Benzylphenethylamine (α-NBOMe) Hallucinogens. Current Topics in Behavioral Neurosciences, 2017, 32, 283-311.	0.8	76
14	N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT ₂ Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues. ACS Chemical Neuroscience, 2015, 6, 1165-1175.	1.7	69
15	Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-lysergic acid diethylamide (1P-LSD). Drug Testing and Analysis, 2016, 8, 891-902.	1.6	64
16	Effect of Hallucinogens on Unconditioned Behavior. Current Topics in Behavioral Neurosciences, 2016, 36, 159-199.	0.8	63
17	LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT _{2A} receptor. Psychopharmacology, 2010, 208, 179-189.	1.5	62
18	Chronic pain and psychedelics: a review and proposed mechanism of action. Regional Anesthesia and Pain Medicine, 2020, 45, 486-494.	1.1	62

#	ARTICLE	IF	CITATIONS
19	Investigation of the Structure-Activity Relationships of Psilocybin Analogues. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 533-542.	2.5	58
20	Pharmacological Investigations of the Dissociative "Legal Highs"™ Diphenidine, Methoxphenidine and Analogues. <i>PLoS ONE</i> , 2016, 11, e0157021.	1.1	55
21	Hallucinations Under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison. <i>Schizophrenia Bulletin</i> , 2020, 46, 1396-1408.	2.3	55
22	Serotonergic hallucinogens as translational models relevant to schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 2165-2180.	1.0	51
23	Return of the lysergamides. Part II: Analytical and behavioural characterization of 6-allylnorlysergic acid diethylamide (AL-LAD) and (2S,4S)-lysergic acid 2,4-dimethylazetidine (LSZ). <i>Drug Testing and Analysis</i> , 2017, 9, 38-50.	1.5	51
24	Synthesis and Biological Evaluation of Tryptamines Found in Hallucinogenic Mushrooms: Norbaecocystin, Baecocystin, Norpsilocin, and Aeruginascin. <i>Journal of Natural Products</i> , 2020, 83, 461-467.	1.5	47
25	Premature responses in the five-choice serial reaction time task reflect rodents' temporal strategies: evidence from no-light and pharmacological challenges. <i>Psychopharmacology</i> , 2016, 233, 3513-3525.	1.5	45
26	Return of the lysergamides. Part V: Analytical and behavioural characterization of 1- <i>n</i> -butanoylnorlysergic acid diethylamide (1B-LSD). <i>Drug Testing and Analysis</i> , 2019, 11, 1122-1133.	1.6	43
27	Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors. <i>Psychopharmacology</i> , 2008, 201, 55-66.	1.5	42
28	Role of the 5-HT _{2A} receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice. <i>Neuropharmacology</i> , 2013, 70, 218-227.	2.0	42
29	Dopamine depletion attenuates some behavioral abnormalities in a hyperdopaminergic mouse model of bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 155, 247-254.	2.0	41
30	Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). <i>Drug Testing and Analysis</i> , 2018, 10, 310-322.	1.6	40
31	Enhanced effects of amphetamine but reduced effects of the hallucinogen, 5-MeO-DMT, on locomotor activity in 5-HT _{1A} receptor knockout mice: Implications for schizophrenia. <i>Neuropharmacology</i> , 2011, 61, 209-216.	2.0	39
32	BDNF-Deficient Mice Show Reduced Psychosis-Related Behaviors Following Chronic Methamphetamine. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv116.	1.0	37
33	Habituation and sensitization of acoustic startle: Opposite influences of dopamine D1 and D2-family receptors. <i>Neurobiology of Learning and Memory</i> , 2009, 92, 243-248.	1.0	36
34	The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents. <i>Psychopharmacology</i> , 2016, 233, 1215-1225.	1.5	35
35	Effect of 5-HT _{2A} and 5-HT _{2C} receptors on temporal discrimination by mice. <i>Neuropharmacology</i> , 2016, 107, 364-375.	2.0	34
36	Behavioral effects of 1±,1±,1±,1±-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. <i>Psychopharmacology</i> , 2012, 221, 709-718.	1.5	33

#	ARTICLE	IF	CITATIONS
37	Return of the lysergamides. Part III: Analytical characterization of 6-ethylnorlysergic acid diethylamide (ETHLAD) and 1-propionyl ETHLAD (1PETHLAD). <i>Drug Testing and Analysis</i> , 2017, 9, 1641-1649.	1.6	33
38	Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs. <i>Neuropharmacology</i> , 2018, 142, 231-239.	2.0	31
39	Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in mice. <i>Psychopharmacology</i> , 2011, 215, 81-92.	1.5	28
40	Automated detection of the head-twitch response using wavelet scalograms and a deep convolutional neural network. <i>Scientific Reports</i> , 2020, 10, 8344.	1.6	27
41	Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 143, 1-10.	1.3	23
42	Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of -lysergic acid diethylamide (LSD). <i>Neuropharmacology</i> , 2020, 172, 107856.	2.0	22
43	A novel visuospatial priming task for rats with relevance to Tourette syndrome and modulation of dopamine levels. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1139-1149.	2.9	21
44	Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). <i>Psychopharmacology</i> , 2019, 236, 799-808.	1.5	21
45	Convergent neural substrates of inattention in bipolar disorder patients and dopamine transporter-deficient mice using the 5-choice CPT. <i>Bipolar Disorders</i> , 2020, 22, 46-58.	1.1	21
46	Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran (FLY) and benzodifuran (DragonFLY) analogs. <i>Neuropharmacology</i> , 2019, 144, 368-376.	2.0	20
47	Chronic treatment with a metabotropic mGlu2/3 receptor agonist diminishes behavioral response to a phenethylamine hallucinogen. <i>Psychopharmacology</i> , 2019, 236, 821-830.	1.5	19
48	Selective anterograde tracing of nonserotonergic projections from dorsal raphe nucleus to the basal forebrain and extended amygdala. <i>Journal of Chemical Neuroanatomy</i> , 2008, 35, 317-325.	1.0	18
49	Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice. <i>Journal of Psychopharmacology</i> , 2019, 33, 406-414.	2.0	18
50	Acute serotonin 2A receptor activation impairs behavioral flexibility in mice. <i>Behavioural Brain Research</i> , 2020, 395, 112861.	1.2	18
51	Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-1-d-lysergic acid diethylamide (1CPDSD). <i>Drug Testing and Analysis</i> , 2020, 12, 812-826.	1.6	17
52	Projections from the vestibular nuclei and nucleus prepositus hypoglossi to dorsal raphe nucleus in rats. <i>Neuroscience Letters</i> , 2008, 439, 70-74.	1.0	15
53	The selective 5-HT2A receptor agonist 25CN-NBOH: Structure-activity relationship, in vivo pharmacology, and in vitro and ex vivo binding characteristics of [3H]25CN-NBOH. <i>Biochemical Pharmacology</i> , 2020, 177, 113979.	2.0	15
54	Investigation of the 2,5-Dimethoxy Motif in Phenethylamine Serotonin 2A Receptor Agonists. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1238-1244.	1.7	11

#	ARTICLE	IF	CITATIONS
55	Analytical characterization of <i>N,N</i> -diethyltryptamine (DAET) and 16 ring-substituted derivatives. <i>Drug Testing and Analysis</i> , 2017, 9, 115-126.	1.6	8
56	(2-Aminopropyl)benzo[<i>b</i>]thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice. <i>Neuropsychopharmacology</i> , 2022, 47, 914-923.	2.8	8
57	Return of the lysergamides. Part VII: Analytical and behavioural characterization of 1- <i>valeroyl</i> -lysergic acid diethylamide (1- <i>VLSD</i>). <i>Drug Testing and Analysis</i> , 2022, 14, 733-740. ^{1.6}	1.6	8
58	Hippocampal serotonin depletion unmasks differences in the hyperlocomotor effects of phencyclidine and MK-801: quantitative versus qualitative analyses. <i>Frontiers in Pharmacology</i> , 2013, 4, 109.	1.6	7
59	Hallucinogenic Drugs: A New Study Answers Old Questions about LSD. <i>Current Biology</i> , 2017, 27, R156-R158.	1.8	7
60	Chemoenzymatic Synthesis of 5-Methylpsilocybin: A Tryptamine with Potential Psychedelic Activity. <i>Journal of Natural Products</i> , 2021, 84, 1403-1408.	1.5	7
61	Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1- <i>ALAD</i> . <i>Drug Testing and Analysis</i> , 2022, 14, 1503-1518.	1.6	7
62	HIV Transgenic Rats Demonstrate Impaired Sensorimotor Gating But Are Insensitive to Cannabinoid (<i>9</i> -Tetrahydrocannabinol)-Induced Deficits. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 894-906.	1.0	6
63	Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 102, 88-94.	1.3	4
64	Effects of the psychotomimetic benzomorphan <i>N</i> -allylnormetazocine (SKF 10,047) on prepulse inhibition of startle in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 148, 69-75.	1.3	4
65	Analytical profile of <i>N</i> -ethyl- <i>N</i> -cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ). <i>Drug Testing and Analysis</i> , 2020, 12, 1514-1521.	1.6	4
66	2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α 2-adrenergic receptors. <i>Psychopharmacology</i> , 2019, 236, 989-999.	1.5	3
67	Syntheses and analytical characterizations of novel (2-aminopropyl)benzo[<i>b</i>]thiophene (APBT) based stimulants. <i>Drug Testing and Analysis</i> , 2020, 12, 1109-1125.	1.6	2
68	Pharmacological characterizations of the 'legal high' fluorolintane and isomers. <i>European Journal of Pharmacology</i> , 2019, 857, 172427.	1.7	1
69	Response to Mukhdomi and Mukhdomi's letter to the editor. <i>Regional Anesthesia and Pain Medicine</i> , 2021, 46, 557-558.	1.1	0